All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

SWOG1826: What are the key takeaways?

Dec 28, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in treatments for older patients (≥60 years) with advanced-stage hodgkin lymphoma.

Bookmark this article

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sarah Rutherford, Weill Cornell Medicine, New York, US. We asked, SWOG1826: What are the key takeaways?

SWOG1826: What are the key takeaways?

Firstly, Rutherford discusses key findings from SWOGS1826 which investigated nivolumab-AVD (N-AVD) versus brentuximab vedotin-AVD (Bv-AVD) in older patients (≥60 years) with advanced Hodgkin lymphoma. She highlights the positive tolerability results for N-AVD therapy compared with Bv-AVD, citing fewer adverse events with N-AVD, such as nausea, diarrhea, and sepsis infections. She then outlines the promising efficacy data, with 93% of patients in the N-AVD arm achieving progression-free survival, compared with 64% in the Bv-AVD arm.

In conclusion, N-AVD has the potential to be a standard-of-care treatment option for older patients with advanced Hodgkin lymphoma; however, further follow-up is warranted.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox